← Open Payments lookup

NPI 1295739902: Open Payments

NPI 1295739902. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$213 in 10 payments from 8 companies in 2025. Trend: 2023 $282 · 2024 $161 · 2025 $213

Food & beverage: $213
CompanyPaymentsAmount
Vanda Pharmaceuticals Inc.2$62
Xeris Pharmaceuticals, Inc.2$45
Lundbeck LLC1$25
PFIZER INC.1$19
AstraZeneca Pharmaceuticals LP1$19
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)1$15
Amgen Inc.1$14
ABBVIE INC.1$14

Products named: FANAPT, RECORLEV, REXULTI, NURTEC ODT, FARXIGA, CAPLYTA, OTEZLA, VRAYLAR.